Pharmacovigilance – News and Features

Experts from Stellenbosch University have highlighted the role that genetics may play in treating the current global tuberculosis pandemic.

The Company to start Phase 1 human safety study of its investigational eiRNA therapy for the treatment of chronic hepatitis B infection.

The SBIR $233,598 Phase I grant will be used to develop high throughput technology targeting Tau OLIGOMERS.

Lumera extends the collaboration agreement and gain rights to commercialize the jointly developed intellectual property.

ChanTest's primary focus is on ion channels that may be either deliberate therapeutic targets for new drug development, or unintended targets that can result in unwanted side-effects from new drugs.

Johns Hopkins researchers’ experiments in ultra-small channels unlock secrets in yeast behavior that nayy lead to cancer or other illnesses.

The phase 2a study is designed to assess the safety, tolerability, pharmacokinetics and efficacy and to further define the clinical profile of ALKS 27 in patients with COPD.

University of Leicester scientists have identified two genes associated with redness and peeling of the skin during cancer treatment.

Sainsbury Laboratory scientists will lead an €11.8-million research consortium that will study the potential uses for RNA interference in treating disease.

The US FDA has cleared a Cepheid’s PCR test which is designed to detect nosocomial and antibiotic-resistant strain of Staphylococcus in over one hour.